Anatomic Stage I Breast CancerPhase 2NCT05919108
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
A Phase 2 study testing Endocrine Therapy, Biopsy of breast and Neratinib in people with Anatomic Stage I Breast Cancer and Anatomic Stage II Breast Cancer, run by Vanderbilt-Ingram Cancer Center at 5 sites in United States.
Trial summary
This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of medications called kinase inhibitors. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer
- What is being tested?
- Endocrine Therapy, Biopsy of breast and Neratinib
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 5 sitesUnited States
- Study dates
- 11 Jun 2024to 30 Apr 2031
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Each patient will be entered into this study only if all of these criteria are met:
- Subjects aged 18 years or older at signing of informed consent.
- New diagnosis of clinical stage I-III HR+ histologically-proven (i.e. absent or decreased e-cadherin expression) invasive lobular carcinoma
- Synchronous breast tumors are permitted as long as the synchronous tumor is ER+ and HER2-negative.
- ER+ disease defined as ≥1% estrogen receptor (ER) positive consistent with current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) or European Society of Medical Oncology (ESMO) guidelines)
- At the time of screening, histologically confirmed cancers in patients with previously documented activating HER2 mutation (see Appendix A) confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalent laboratory.
Show all 24Show fewer
- Archival tissue availability (if not available a fresh tumor biopsy will be required) and subject must agree to submission of sample for central testing
- Minimum tumor size of ≥1.5 cm by US, mammogram, MRI imaging, or clinical breast exam
- ECOG performance status 0 or 1
- Patients must have adequate hematologic, hepatic, and renal function. All laboratory tests must be obtained within 1 month of study entry. This includes:
- Estimated glomerular filtration rate of ≥50 mL/min
- Albumin ≥ 2.5 g/dL
- ANC ≥1500/mm^3
- Platelet count ≥100,000/mm^3
- HgB ≥ 9 g/dL
- Total serum bilirubin ≤ 1.5 x ULN (in patients with known Gilbert Syndrome, a total bilirubin ≤ 3.0 x ULN, with direct bilirubin ≤ 1.5 x ULN)
- AST and ALT ≤ 3 x ULN
- Pre-, peri-, or post-menopausal, confirmed by history or laboratory testing as needed
- Diagnostic biopsy tissue availability with sufficient tumor to permit NGS (if not available, a fresh biopsy will be required)
- No prior treatment for current diagnosis of breast cancer
- For patients who are not postmenopausal (women) or surgically sterile (absence of ovaries and/or uterus or vasectomy), agreement to remain abstinent or to use two adequate methods of contraception (e.g., condoms, diaphragm, vasectomy/vasectomized partner, tubal ligation), during the treatment period and for at least 30 days after the last dose of study treatment. Hormone based oral contraceptives are not allowed on study. Postmenopausal is defined as:
- Age ≥ 55 years
- Age ≤ 55 years and amenorrheic for 12 months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression; or follicle stimulating hormone and estradiol in the postmenopausal range. Female participants of childbearing potential are eligible to participate if they agree to use a highly effective method of contraception that has a low user dependency consistently and correctly.
- Note: The effects of neratinib on the developing fetus are unknown and endocrine therapy is contraindicated in pregnancy. For this reason and because teratogenic effects have been observed in nonclinical studies and neratinib, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of the study participation, and for 1 month after the last dose of study medication. Should a woman become pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation and 3.5 months after completion of study treatment.
Who cannot join
- Evidence of distant metastatic disease
- Synchronous breast cancer that is estrogen receptor negative OR HER2-amplified OR requires treatment with neoadjuvant chemotherapy per the judgement of the treating physician
- Patients harboring ineligible somatic HER2 mutations, such as those that are subclonal in nature or those resulting in the expression of truncated proteins including alterations that result in premature stop codon or a change in reading frame (ie, frame shift mutations).
- Prior endocrine therapy for breast cancer within the last 2 years
- Women who are pregnant, are planning to become pregnant, or are breast-feeding
- Any investigational treatment for the current diagnosis of breast cancer
Show all 14Show fewer
- HER2 amplification by FISH (HER2:CEP17 ratio >2.0) or IHC (HER2 (3+)
- Hepatic function impairment as defined by AST or ALT > 3x ULN OR total serum bilirubin > 1.5 (in patients with known Gilbert syndrome, a total bilirubin of > 3.0 x ULN or direct bilirubin > 1.5 x ULN)
- Significant chronic gastrointestinal disorder with diarrhea as a major symptom (eg, Crohn's disease, malabsorption, or Grade ≥2 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE version 4.0] diarrhea of any etiology at baseline.
- Evidence of significant medical illness, abnormal laboratory finding, or psychiatric illness/social situations that could, in the Investigator's judgment, make the patient inappropriate for this study.
- Known hypersensitivity to any component of the investigational product, required combination therapy, or loperamide.
- Unable or unwilling to swallow tablets.
- Unable or unwilling to complete study procedures such as research biopsies or imaging
- Any medical condition that in the judgement of the co-investigator would impair the patient's ability to complete the planned study therapy
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
United States5 sites, 5 recruiting
- Not yet recruiting
Emory University/ Winship Cancer Institute
Atlanta, Georgia, 30322
Kevin Kalinsky, MD
- Recruiting
University of Texas, Southwestern
Dallas, Texas, 75390
Nisha Unni, Nisha.Unni@UTSouthwestern.edu
Carlos Arteaga, MD
- Not yet recruiting
Baylor College of Medicine
Houston, Texas, 77030
Bora Lim, MD
- Recruiting
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37203
Vanderbilt-Ingram Service for Timely Access, 800-811-8480, cip@vumc.org
Laura Kennedy, MD, PhD
- Not yet recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213
Adam Brufsky, MD
About this study
This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving neratinib in addition to normal therapy may work better in treating cancer than the endocrine therapy patients would normally receive.
Read the detailed description
PRIMARY OBJECTIVE:
- Determine efficacy of neoadjuvant neratinib in combination with endocrine therapy.
SECONDARY OBJECTIVES:
- Determine additional efficacy outcomes of neoadjuvant neratinib in combination with endocrine therapy.
II. Compare the safety and tolerability of neratinib plus endocrine therapy.
CORRELATIVE OBJECTIVE:
- Establish HER2-mutant invasive lobular carcinoma (ILC) organoids.
OUTLINE: Patients are randomized to 1 of 2 treatments.
TREATMENT A: Patients receive standard of care endocrine therapy over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then endocrine therapy and neratinib orally (PO) daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast magnetic resonance imaging (MRI) prior to surgery.
TREATMENT B: Patients receive standard of care endocrine therapy and neratinib PO over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then continue endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery.
After completion of study treatment, patients are followed up for 4 weeks after study drugs interruption.
- Conditions
- Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
- Being tested
- Endocrine Therapy, Biopsy of breast, Neratinib, Biospecimen Collection, Mammogram
- Medical subject headings
- Carcinoma, Lobular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endocrine TherapyProcedure or surgery
Undergo endocrine therapy
Biopsy of breastProcedure or surgery
Undergo breast biopsy
NeratinibDrug
Taken by mouth
Biospecimen CollectionProcedure or surgery
Undergo collection of blood samples
MammogramProcedure or surgery
Undergo Mammogram
Magnetic Resonance ImagingProcedure or surgery
Undergo breast Magnetic Resonance Imaging
Breast SurgeryProcedure or surgery
Undergo Breast Surgery
UltrasoundProcedure or surgery
Undergo Ultrasound
| Study group | Role | What they receive |
|---|---|---|
| Treatment A (endocrine therapy) | Active comparator | Patients receive standard of care endocrine therapy over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery. Receives: Procedure: Endocrine Therapy; Procedure: Biopsy of breast; Drug: Neratinib; Procedure: Biospecimen Collection; Procedure: Mammogram; Procedure: Magnetic Resonance Imaging; Procedure: Breast Surgery |
| Treatment B (endocrine therapy, neratinib) | Experimental | Patients receive standard of care endocrine therapy and neratinib PO over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then continue endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery. Receives: Procedure: Endocrine Therapy; Procedure: Biopsy of breast; Drug: Neratinib; Procedure: Biospecimen Collection; Procedure: Mammogram; Procedure: Magnetic Resonance Imaging; Procedure: Breast Surgery; Procedure: Ultrasound |
What is being measured
The primary outcome is the main question the study is designed to answer.
Preoperative endocrine prognostic index score
Measured: Up to 5 years
Secondary outcomes (5)
Pathological complete response rate
Will be summarized for the entire cohort by response.
Measured: Up to 5 years
Change in Ki67
Measured: At 4 weeks
Residual cancer burden index
Will be summarized for the entire cohort by response
Measured: Up to 5 years
Rates of breast conservation therapy
Will be summarized for the entire cohort by response
Measured: Up to 5 years
Incidence of adverse events (NCI Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)
Measured: Up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2023
- Study start11 Jun 2024
- Primary completion30 Apr 2030 (estimated)
- Study completion30 Apr 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anatomic Stage I Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), Puma Biotechnology, Inc.
- Responsible party
- Principal investigator, Laura Kennedy, Vanderbilt-Ingram Cancer Center
- Investigators
- Laura Kennedy, MD, PhD, Principal investigator, Vanderbilt University/Ingram Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05919108
- Sponsor's protocol ID
- VICC-NCBRE23172
- Other IDs
- NCI-2023-04468, 1R01CA273246-01A1
- Status last verified
- Aug 2026
- First submitted
- 15 Jun 2023
- Last updated
- 19 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
- ClinicalTrials.gov ID
- NCT05919108
- Acronym / sponsor ID
- VICC-NCBRE23172
- Conditions
- Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Vanderbilt-Ingram Cancer CenterUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), Puma Biotechnology, Inc.
- Study start
- 11 Jun 2024 (actual)
- Primary completion
- 30 Apr 2030 (estimated)
- Study completion
- 30 Apr 2031 (estimated)
- First posted
- 26 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving neratinib in addition to normal therapy may work better in treating cancer than the endocrine therapy patients would normally receive.
Detailed description
PRIMARY OBJECTIVE:
- Determine efficacy of neoadjuvant neratinib in combination with endocrine therapy.
SECONDARY OBJECTIVES:
- Determine additional efficacy outcomes of neoadjuvant neratinib in combination with endocrine therapy.
II. Compare the safety and tolerability of neratinib plus endocrine therapy.
CORRELATIVE OBJECTIVE:
- Establish HER2-mutant invasive lobular carcinoma (ILC) organoids.
OUTLINE: Patients are randomized to 1 of 2 treatments.
TREATMENT A: Patients receive standard of care endocrine therapy over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then endocrine therapy and neratinib orally (PO) daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast magnetic resonance imaging (MRI) prior to surgery.
TREATMENT B: Patients receive standard of care endocrine therapy and neratinib PO over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then continue endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery.
After completion of study treatment, patients are followed up for 4 weeks after study drugs interruption.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment A (endocrine therapy) | Active comparator | Procedure: Endocrine Therapy, Procedure: Biopsy of breast, Drug: Neratinib, Procedure: Biospecimen Collection, Procedure: Mammogram, Procedure: Magnetic Resonance Imaging, Procedure: Breast SurgeryPatients receive standard of care endocrine therapy over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery. |
| Treatment B (endocrine therapy, neratinib) | Experimental | Procedure: Endocrine Therapy, Procedure: Biopsy of breast, Drug: Neratinib, Procedure: Biospecimen Collection, Procedure: Mammogram, Procedure: Magnetic Resonance Imaging, Procedure: Breast Surgery, Procedure: UltrasoundPatients receive standard of care endocrine therapy and neratinib PO over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then continue endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (24 listed)
- Subjects aged 18 years or older at signing of informed consent.
- New diagnosis of clinical stage I-III HR+ histologically-proven (i.e. absent or decreased e-cadherin expression) invasive lobular carcinoma
- Synchronous breast tumors are permitted as long as the synchronous tumor is ER+ and HER2-negative.
- ER+ disease defined as ≥1% estrogen receptor (ER) positive consistent with current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) or European Society of Medical Oncology (ESMO) guidelines)
- At the time of screening, histologically confirmed cancers in patients with previously documented activating HER2 mutation (see Appendix A) confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalent laboratory.
Key exclusion criteria (14 listed)
- Evidence of distant metastatic disease
- Synchronous breast cancer that is estrogen receptor negative OR HER2-amplified OR requires treatment with neoadjuvant chemotherapy per the judgement of the treating physician
- Patients harboring ineligible somatic HER2 mutations, such as those that are subclonal in nature or those resulting in the expression of truncated proteins including alterations that result in premature stop codon or a change in reading frame (ie, frame shift mutations).
- Prior endocrine therapy for breast cancer within the last 2 years
- Women who are pregnant, are planning to become pregnant, or are breast-feeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Endocrine TherapyUndergo endocrine therapy | Procedure or surgery | Treatment A (endocrine therapy), Treatment B (endocrine therapy, neratinib) |
| Biopsy of breastUndergo breast biopsy | Procedure or surgery | Treatment A (endocrine therapy), Treatment B (endocrine therapy, neratinib) |
| NeratinibTaken by mouth | Drug | Treatment A (endocrine therapy), Treatment B (endocrine therapy, neratinib) |
| Biospecimen CollectionUndergo collection of blood samples | Procedure or surgery | Treatment A (endocrine therapy), Treatment B (endocrine therapy, neratinib) |
| MammogramUndergo Mammogram | Procedure or surgery | Treatment A (endocrine therapy), Treatment B (endocrine therapy, neratinib) |
| Magnetic Resonance ImagingUndergo breast Magnetic Resonance Imaging | Procedure or surgery | Treatment A (endocrine therapy), Treatment B (endocrine therapy, neratinib) |
| Breast SurgeryUndergo Breast Surgery | Procedure or surgery | Treatment A (endocrine therapy), Treatment B (endocrine therapy, neratinib) |
| UltrasoundUndergo Ultrasound | Procedure or surgery | Treatment B (endocrine therapy, neratinib) |
Primary outcome
Preoperative endocrine prognostic index score
Time frame: Up to 5 years
5 secondary outcomes
Pathological complete response rate
Time frame: Up to 5 years
Change in Ki67
Time frame: At 4 weeks
Residual cancer burden index
Time frame: Up to 5 years
Rates of breast conservation therapy
Time frame: Up to 5 years
Incidence of adverse events (NCI Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)
Time frame: Up to 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Anatomic Stage I Breast Cancer
RecruitingPhase 2
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma
Active, not recruitingPhase 2
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
RecruitingPhase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Not yet recruiting
De-escalation of Axillary Dissection for Node-positive Breast Cancer
Breast Cancer by AJCC V8 Anatomic Stage, Breast Cancer
RecruitingPhase 2
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Laura Kennedy, MD, PhD principal investigator
Vanderbilt University/Ingram Cancer Center
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Endocrine Therapy, Biopsy of breast and Neratinib in people with Anatomic Stage I Breast Cancer and Anatomic Stage II Breast Cancer, run by Vanderbilt-Ingram Cancer Center at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 24 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Vanderbilt-Ingram Services for Timely Access (800-811-8480, cip@vumc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Preoperative endocrine prognostic index score (time frame: Up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026; AzTrials last refreshed its copy on 6 Nov 2026.